No difference in Admission Free Survival at 12 Months

Murphy - Figure 11

FIG. 11: So it is clear that there is no beneficial change in admission-free survival at 12 months when home NIV is administered to all patients who remain hypercapnic at the end of their acute exacerbation.[13] The question remains, however, whether there might be subgroups of patients who may benefit from this intervention.[14]

Murphy P. Chest 2017:00.

References

[13]

Struik FM, Sprooten RT, Kerstjens HAM, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomized, controlled, parallel-group study. Thorax. 2014;69:826−34. doi: 10.1136/thoraxjnl-2014-205126.

[14]

Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med. 1997;102:239−44.